RAD23B and colorectal carcinoma: At the PRM and immunoassay verification stages of this study, a panel of three urinary biomarkers (CORO1C, ARPC5, and RAD23B) for CRC diagnosis and a panel of four urinary biomarkers (CORO1C, RAD23B, GSPT5, and NDN) for CRC metastatic risk stratification were defined.